エストロゲン置換療法は,閉経後の女性の血管交感性流出のバロレフレクスの調節を改善します
B E Hunt1, J A Taylor, J W Hamner
1Laboratory for Cardiovascular Research, Research and Training Institute, Hebrew Rehabilitation Center for Aged, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA. hunt@mail.hrca.harvard.edu
Circulation
|June 20, 2001
まとめ
閉経後の女性のエストロゲン置換療法は,休息時の血圧を変化させなかったが,交感性バロレフレクスの増加を高め,単純な圧力変化を超えて心血管の調節効果を示唆した.
科学分野:
- 心血管生理学 心血管の生理学
- エンドクリノロジー エンドクリノロジー
- 女性健康 女性の健康
背景:
- 閉経時のエストロゲン損失は,女性の心血管疾患リスクの増加と関連しています.
- 精密なメカニズム,特に動脈圧の調節に関するメカニズムは不明のままです.
- 高齢の女性の動脈圧に対するエストロゲンの影響に関する既存のデータは矛盾しています.
研究 の 目的:
- 閉経後の女性の動脈圧とバロレフレクスの調節に対する長期的なエストロゲン置換療法の影響を調査する.
- エストロゲンが血管交感神経の活動と,その調節的役割を影響するかどうかを判断する.
主な方法:
- エストロゲン投与の6ヶ月前と後の11人の健康な閉経後の女性を研究しました.
- 静脈圧は,アウスクルテーションとフォトプレチスモグラフィーを用いて測定したものです.
- マイクロニューログラフィと薬理学的注入を使用して,血管交感神経の活動とバロレフレクスの増加を評価しました.
主要な成果:
- エストロゲン療法は,静止状態のシストリック血圧や心回体バロレフレクスの増加を有意に変化させなかった.
- 血管交感性バロレフレクスの獲得の有意な増加が観察されました (P=0.02).
結論:
- 長期にわたるエストロゲン置換療法は,心血管の調節に影響を与えます.
- 自律的制御に対するこれらの影響は,静止状態の動脈圧測定では明らかでない場合があります.
関連する概念動画
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Menopause
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
Aortic Regurgitation III: Medical Management
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...


